Eleven Biotherapeutics (EBIO) Posts Smaller Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eleven Biotherapeutics Reports First Quarter 2015 Financial Results
April 30, 2015 7:30 AM EDTManagement to host conference call today at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2015, and recent business highlights.
"Recently, weve presented and published a comprehensive body of clinical data related to Elevens ocular therapeutics pipeline in peer-reviewed journals and at ocular disease meetings, said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. These... More
